Evaluation of canonical siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication--a comparative study.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4338191)

Published in PLoS One on February 23, 2015

Authors

Bruno Carneiro1, Ana Cláudia Silva Braga2, Mariana Nogueira Batista2, Mark Harris3, Paula Rahal2

Author Affiliations

1: Genomics Study Laboratory, Sao Paulo State University, IBILCE, São José do Rio Preto, SP, Brazil; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom.
2: Genomics Study Laboratory, Sao Paulo State University, IBILCE, São José do Rio Preto, SP, Brazil.
3: School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom.

Articles citing this

Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90. Cell Stress Chaperones (2016) 0.75

Articles cited by this

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56

RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16

RNA interference. Nature (2002) 22.28

Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63

Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16

Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56

Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci (2001) 6.66

Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48

Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res (2004) 5.46

RNA virus populations as quasispecies. Curr Top Microbiol Immunol (1992) 5.42

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 4.85

Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A (2003) 3.74

Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71

RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21

An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun (2004) 2.84

Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83

Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64

RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14

Dicer-2 and R2D2 coordinately bind siRNA to promote assembly of the siRISC complexes. RNA (2006) 1.98

The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem (2003) 1.93

Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol (2006) 1.87

RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A (2003) 1.84

Hepatitis C virus biology. Cell Death Differ (2003) 1.83

Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol (2005) 1.55

Role of oxysterol binding protein in hepatitis C virus infection. J Virol (2009) 1.43

An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37

Enhanced chemiluminescence (ECL) for routine immunoblotting: An inexpensive alternative to commercially available kits. Spermatogenesis (2011) 1.31

Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int (2012) 1.30

Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol (2005) 1.24

Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther (2007) 1.09

The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother (2009) 1.03

siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J Viral Hepat (2006) 1.01

Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA (2012) 0.98

The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis (2014) 0.97

Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol (2000) 0.95

Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res (2006) 0.95

Inhibition of hepatitis C virus protein expression by RNA interference. Virus Res (2003) 0.93

The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release. J Gen Virol (2013) 0.92

Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. Nucleic Acids Res (2010) 0.91

RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci Biotechnol Biochem (2006) 0.90

Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J (2006) 0.89

Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res (2013) 0.88

RNAi as a new therapeutic strategy against HCV. Biotechnol Adv (2009) 0.87

Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. J Med Virol (2005) 0.87

Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol (2004) 0.86

HIV-1 Escape From RNAi Antivirals: Yet Another Houdini Action? Mol Ther Nucleic Acids (2012) 0.84

Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. J Virol (2014) 0.84

Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes. Pharmacol Res (2011) 0.78

Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome. Ann Hepatol (2007) 0.77

42- and 63-bp anti-MDR1-siRNAs bearing 2'-OMe modifications in nuclease-sensitive sites induce specific and potent gene silencing. FEBS Lett (2014) 0.76